FREEPORT, The Bahamas (PRWEB) February 28, 2013
Okyanos Heart Institute, which brings a new standard of care and better quality of life to patients with chronic coronary artery disease using cardiac stem cell therapy, announces that Chief Medical Officer Howard Walpole Jr., M.D., MBA, FACC, FACAI will speak at The American College of Cardiology’s (ACC’s) 13th Annual Scientific Session. Dr. Walpole will join a panel of experts on the topic of “Readmission Reduction: Why Should You Care?” The session features thought leaders who will provide the latest data on successful readmission strategies. They will incorporate case studies and results from Medicare's recent test project, and an emphasis on care coordination with a proven track record in reducing readmissions in three index conditions: heart failure, acute myocardial infarction, and pneumonia. The session will be held from 12:30 p.m. to 1:45 p.m. on Sunday, March 10 at the Moscone Center in San Francisco.
“Readmissions for the three index conditions account for over $17 billion a year (in 2004) in health care expenses,” said Cathleen Biga, chief executive officer of Cardiovascular Management of Illinois (CMI) and the chair of the session. “Hospitals readmit nearly one in five Medicare patients within one month of discharge. Since October 1, 2012, over 2,200 hospitals are facing penalties (payment adjustments) totaling over $280 million, making this topic one of the most important, if not the most important topic of 2013.”
“I am looking forward to bringing this important discussion to the ACC conference,” said Walpole. “My topic in the discussion will be about reducing heart failure readmissions using a case study method to help participants through this transformative area of healthcare.”
More information about the event can be found at http://www.cardiosource.org/acc
ABOUT OKYANOS HEART INSTITUTE:
Based in Freeport, The Bahamas, Okyanos Heart Institute adheres to U.S. surgical center standards and is led by Chief Medical Officer Howard T. Walpole Jr., M.D., MBA, FACC, FACAI, and a leader of the American College of Cardiology for many years. The mission of Okyanos Heart Institute is to bring a new standard of care and a better quality of life to patients with chronic coronary artery disease using cardiac stem cell therapy. Okyanos Treatment utilizes cardiac stem cell therapy, a unique blend of stem and regenerative cells to support the growth of new blood vessels and to assist the heart in repairing tissue damaged by heart attack and disease. The Greek god of rivers, “Okyanos” symbolizes the primary mechanism of action that these adult stem cells have on ischemic (lack of blood flow) heart tissue, the result of the plaque deposits in the coronary arteries. The stem cells, derived from a person’s adipose (fat) tissue, create new blood vessels, a process known as angiogenesis. The treatment helps to facilitate blood flow in the heart and intake and use of oxygen, as measured by a rigorous clinical trial known as the PRECISE trial, as well as cardiac cell therapy trials at leading research institutions. For more information, log on to http://www.okyanos.com/.